机译:与Daratumumab,Bortezomib,Melphalan和泼尼松在新诊断的多发性骨髓瘤(Alcyone)中的整体生存(alcyone):随机,开放标签,第3阶段试验
Hosp Univ Salamanca Inst Invest Biomed Salamanca IBSAL Salamanca 37007 Spain;
Bologna Univ Sch Med Seragnoli Inst Hematol Bologna Italy;
Univ Barcelona IDIBAPS Hosp Clin Barcelona Barcelona Spain;
Univ Athens Athens Greece;
Japanese Red Cross Med Ctr Dept Hematol Tokyo Japan;
Univ Chicago Med Ctr Chicago IL 60637 USA;
Wurzburg Univ Med Ctr Wurzburg Germany;
Catholic Univ Louvain CHU UCL Namur Yvoir Belgium;
Champalimaud Ctr Unknown Lisbon Portugal;
Semmelweis Univ Dept Med 1 Budapest Hungary;
Univ Hosp Brno Brno Czech Republic;
Univ Hosp Birmingham NHSTrust Birmingham W Midlands England;
Med Univ Silesia Chorzow Sch Publ Hlth Dept Hematol &
Canc Prevent Katowice Poland;
Clin Tratamento &
Pesquisa Hematol &
Oncol Cuiaba Brazil;
Azienda Osped Santa Maria Terni Terni Italy;
Andrew Love Canc Ctr Geelong Vic Australia;
Clin Profess Pathol Saratov Russia;
Seoul Natl Univ Coll Med Dept Internal Med Seoul South Korea;
Medinvent Inst Hlth Tbilisi Georgia;
Matsuyama Red Cross Hosp Matsuyama Ehime Japan;
Leicester Royal Infirm Dept Haematol Leicester Leics England;
Janssen Res &
Dev Spring House PA USA;
Janssen Res &
Dev Raritan NJ USA;
Janssen Res &
Dev Raritan NJ USA;
Janssen Res &
Dev Raritan NJ USA;
Janssen Global Med Affairs Horsham PA USA;
Janssen Res &
Dev Spring House PA USA;
Janssen Res &
Dev Raritan NJ USA;
Univ Navarra CIMA Inst Invest Sanitaria Navarra IDISNA Ctr Invest Biomed Red Oncol CIBERONC;
机译:与Daratumumab,Bortezomib,Melphalan和泼尼松在新诊断的多发性骨髓瘤(Alcyone)中的整体生存(alcyone):随机,开放标签,第3阶段试验
机译:在新诊断出多种骨髓瘤(NDMM)患者中,嗜酸甘油醇与硼丙胺,莫尔芬,泼尼松(D-VMP)与甲腺苷与硼葡萄球菌,Melphalan和泼尼松(VMP)组合的比较疗效和安全性
机译:Daratumumab Plus Bortezomib,Melphalan和East Asian患者的非移植多发性骨髓瘤的泼尼松:随机阶段3 alcyone试验的细胞分析
机译:风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松,用于新诊断的未经治疗的全身淀粉样蛋白症患者:II期试验的中期报告
机译:Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物,最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
机译:来那度胺美法仑和泼尼松继之以来那度胺维持可以改善65岁以上新诊断的多发性骨髓瘤患者的健康相关生活质量:一项随机III期试验的结果
机译:Daratumumab Plus Bortezomib,Melphalan和East Asian患者的非移植多发性骨髓瘤的泼尼松:随机阶段3 alcyone试验的细胞分析